JonesTrading analyst Soumit Roy maintained a Buy rating on Cassava Sciences (SAVA – Research Report) today and set a price target of $100.00. The company’s shares opened today at $23.77.
According to TipRanks, Roy is an analyst with an average return of -4.2% and a 26.91% success rate. Roy covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Oncolytics Biotech, and Day One Biopharmaceuticals.
Currently, the analyst consensus on Cassava Sciences is a Moderate Buy with an average price target of $112.00.
See the top stocks recommended by analysts >>
Based on Cassava Sciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $24.27 million. In comparison, last year the company had a GAAP net loss of $17.53 million
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SAVA in relation to earlier this year. Earlier this month, Patrick Phd Scannon, a Director at SAVA bought 1,000.00 shares for a total of $950.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Read More on SAVA:
- New Research Shows Simufilam Suppresses Overactive mTOR
- Cassava Sciences announces publication on effects of simufilam
- Cassava Sciences call volume above normal and directionally bullish
- New Publication Highlights Basic Science Supporting Simufilam
- Cassava Sciences announces publication on basic science supporting simufilam
